Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more
New Patient Portal System
Texas Retina Associates is in the process of transitioning to a new and improved patient portal system that will go live on Wednesday, August 9, 2023. This secure portal will provide you
read more
July is UV Safety Month — Debunking Seven Common Myths About Sunglasses
When most people think of UV protection, they think of their skin and sunscreen. Did you know that long-term exposure to bright sunlight may also increase your risk of eye disease? July
read more
Offices Closed on Tuesday, July 4, 2023
All Texas Retina Associates offices will be closed on Tuesday, July 4, 2023, in recognition of the Independence Day holiday and will reopen on Wednesday, July 5. We wish everyone a safe
read more
June is Fireworks Eye Safety Awareness Month
By Ivan Castillo, MD Summer is here, and for many that means outdoor celebrations that include fireworks, especially around the 4th of July. Unfortunately, this also means an increase in eye injuries.
read more
11 Tips to Protect Men’s Eye Health
June is Men’s Health Month. It was established to help bring awareness to health issues men face and to encourage them to take charge of their health. A number of retinal diseases can affect
read more
Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more
Dr. Wang Participated in Roundtable Discussion on XIPERE Treatment for Macular Edema Associated with Uveitis
At the most recent American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, Texas Retina Associates’ Robert Wang, MD, participated in a roundtable discussion with seven other retina specialists to share their
read more